A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years




TekijätDel Riccio M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV, Teirlinck AC, Wang X, Heikkinen T, Bangert M, Caini S, Campbell H, Paget J; RESCEU investigators

KustantajaOXFORD UNIV PRESS INC

Julkaisuvuosi2023

JournalJournal of Infectious Diseases

Tietokannassa oleva lehden nimiJOURNAL OF INFECTIOUS DISEASES

Lehden akronyymiJ INFECT DIS

Sivujen määrä11

ISSN0022-1899

eISSN1537-6613

DOIhttps://doi.org/10.1093/infdis/jiad188

Verkko-osoitehttps://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad188/7183891

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/180392314


Tiivistelmä

Background

No overall estimate of respiratory syncytial virus (RSV)-associated hospitalizations in children aged under 5 years has been published for the European Union (EU). We aimed to estimate the RSV hospitalization burden in children aged under 5 years in EU countries and Norway, by age group.

Methods

We collated national RSV-associated hospitalization estimates calculated using linear regression models via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands, and Scotland, 2006-2018. Additional estimates were obtained from a systematic review. Using multiple imputation and nearest neighbor matching methods, we estimated overall RSV-associated hospitalizations and rates in the EU.

Results

Additional estimates for 2 countries (France and Spain) were found in the literature. In the EU, an average of 245 244 (95% confidence interval [CI], 224 688-265 799) yearly hospital admissions with a respiratory infection per year were associated with RSV in children aged under 5 years, with most cases occurring among children aged under 1 year (75%). Infants aged under 2 months represented the most affected group (71.6 per 1000 children; 95% CI, 66.6-76.6).

Conclusions

Our findings will help support decisions regarding prevention efforts and represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunization programs in Europe.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 20:43